Drug DiscoveryHematological Disorders June 4, 2024 Pfizer and Abu Dhabi partner to boost sickle cell disease research By PBR Staff Writer The Department of Health (DoH) Abu Dhabi in the UAE has entered into a memorandum of understanding (MoU) with Pfizer Gulf to bolster research in areas including sickle
Research & Development June 3, 2024 Telix seeks BLA for TLX250-CDx aimed at kidney cancer imaging By PBR Staff Writer TLX250-CDx (Zircaix) is the company’s investigational radiodiagnostic PET agent for the renal masses characterisation as ccRCC or non-ccRCC in a non-invasive manner. Initiated in December 2023, the rolling
Drug Discovery May 31, 2024 Weave Bio secures $10m in seed funding round By PBR Staff Writer The company also launched AutoIND, an AI-powered platform designed to optimise the drafting, reviewing, and submitting of regulatory documents in drug development. AutoIND is the first product on
Drug Discovery May 30, 2024 ExpressionEdits secures $13m to develop protein-based therapies By PBR Staff Writer Octopus Ventures and Redalpine co-led the investment round with contributions from Wilbe Capital, BlueYard Capital, Acequia Capital, Amino Collective, and Hawktail. This funding is set to accelerate the
Drug DiscoveryNeurology May 29, 2024 Lucy Therapeutics secures $12.5m for neurological treatment development By PBR Staff Writer The funding round was spearheaded by existing investors Engine Ventures and Safar Partners, with new participations from Bill Gates, Parkinson’s UK, and the Michael J. Fox Foundation, which
Drug Discovery May 28, 2024 RevolKa signs deal with Daiichi Sankyo for functional proteins By PBR Staff Writer Under the terms of the agreement, RevolKa will utilise its protein engineering platform, aiProtein, integrated with artificial intelligence (AI), to create and deliver highly functional proteins. The companies
Women's Health May 27, 2024 EMA validates MAA for Prolia and Xgeva (denosumab) biosimilar candidate HLX14 By PBR Staff Writer Denosumab has secured approval in several countries and regions under different trade names for a range of several indications such as for osteoporosis treatment in postmenopausal women who
Drug DiscoveryResearch and Development (RD) May 24, 2024 Radar Therapeutics secures $13.4m to develop programmable medicines By PBR Staff Writer NfX Bio led the financing which will bolster the company’s development of programmable ribonucleic acid (RNA)-based therapeutics utilising molecular RNA sensors for precise drug delivery. The funding round
Production & SalesLaunches May 23, 2024 Amneal Pharmaceuticals launches supply of Naloxone HCI Nasal Spray in US By PBR Staff Writer The product, which received approval from the US Food and Drug Administration in April 2024, is now available for direct distribution to states and municipalities nationwide. Naloxone HCI
Pharmaceuticals and Healthcare May 22, 2024 AstraZeneca targets $80bn revenue by 2030 By PBR Staff Writer The company said it aims to achieve this target by registering growth in its current portfolio in biopharmaceuticals, oncology, and rare diseases. The effort also includes the launch